Research discovery leads to new clinical trial for myelofibrosis patients

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) discovered in laboratory studies that an experimental drug called selinexor may block a crucial survival pathway exploited by myelofibrosis cells. Their study was published in Clinical Cancer Research, a journal of the American Association of Cancer Research. Based on these findings, they

Read More


England to fast-track tumour agnostic drugs like Vitrakvi – if the price is right Simon

Stevens calls for ‘fair prices’ from companies NHS England’s chief executive Simon Stevens was in Manchester this week at the NHS Confederation conference, delivering his latest vision of what lies ahead for the health service. Among his many announcements, he told NHS managers that patient services would have to continue to evolve, and sent a

Read More


“Nanoemulsion” gels offer new way to deliver drugs through the skin

Novel materials made with FDA-approved components could deliver large payloads of active ingredients. MIT chemical engineers have devised a new way to create very tiny droplets of one liquid suspended within another liquid, known as nanoemulsions. Such emulsions are similar to the mixture that forms when you shake an oil-and-vinegar salad dressing, but with much

Read More


What universities can learn from one of science’s biggest frauds

Source Nature Detailed analysis of misconduct investigations into huge research fraud suggests institutional probes aren’t rigorous enough. By day, Andrew Grey studies bone health. But over the past few years, he’s developed another speciality: the case of one of science’s most prolific fraudsters. From 1996 to 2013, Yoshihiro Sato, a Japanese bone-health researcher plagiarized work,

Read More


New clues on tissue damage identified in rheumatoid arthritis and lupus

Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. Findings include the identification of novel molecular signatures related to immune system signaling in kidney cells that may reflect their active role in disease process; molecular targets, including specific white blood

Read More


FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks

The U.S. Food and Drug Administration today approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults.  “Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Eric Bastings, M.D., deputy director of the

Read More